



InfraScan, Inc. is a medical device start-up with the potential to become a leader in handheld diagnostic imaging devices. InfraScan is developing its flagship product, the Hematoscope™, which is a hand-held imaging device using near infrared (NIR) technologies for the detection of hematoma, or bleeding in the brain, in head trauma patients.

An estimated two million individuals seek medical treatment for head trauma in the U.S. each year, and the worldwide incidence is estimated at around ten million. While CT scans are currently the diagnostic gold standard for hematomas, many head trauma patients do not immediately receive a CT scan. Yet for patients with brain hematomas, prompt remedial action is essential to maximize preservation of life and brain function. In addition, the high cost of CT examinations highlights the need for an accessible, low cost alternative for effectively identifying those patients that actually need a CT scan from those that do not. The Hematoscope will address this unmet medical need for a simple, low-cost, accurate hematoma detection device for use in a variety of settings, including hospital emergency rooms and ICU units. It has the additional advantage of convenience as a bed-side application, since it doesn't require patients to be transported to a central imaging center. The Hematoscope also has potential for use in emergency medical vehicles, in developing world medical clinics and in war and disaster zones.

Based on the patented work of Dr. Britton Chance at the University of Pennsylvania and Dr. Claudia Robertson at Baylor College of Medicine, the Hematoscope unit is a small, portable, handheld device based on a PDA platform with a wireless detector probe. It detects hematoma based on the differential NIR light absorption of the bleeding versus the non-bleeding part of the brain, made possible by the unique light-absorbing property of the hemoglobin in the blood. A pilot study of the technology involving more than 300 patients demonstrated its excellent sensitivity for detecting bleeding in the brain, with no false positive results and better performance than conventional monitoring methods in rapidly detecting late onset bleeding. InfraScan expects to receive revenues from sales of both the Hematoscope device and its disposable probes.

In collaboration with scientists at Drexel University and the University of Pennsylvania, InfraScan will use its BioAdvance Greenhouse funding to support further product development and testing.

Management

Baruch Ben Dor, Ph.D., President and CEO, has over 17 years marketing and management experience in the electro-optics field in both the defense and medical equipment industries. Previously, Dr. Ben Dor was general manager of ophthalmic digital photography start-up Medibell Medical Vision Technologies. Dr. Ben Dor was the global vascular program director for ESC/Sharplan, a worldwide leader in medical lasers. Dr. Ben Dor holds a Ph.D. in Physics from the Technion in Israel and is a graduate of the prestigious "Talpiot" academy of the Israeli Air Force.

Samonnoi Banerjee, Vice President of Business Development, formerly a pharmaceutical and medical device firm consultant at McKinsey & Company and Accenture, is currently pursuing an MBA degree from the Wharton School of Business. He received a Bachelors degree and an M.S. degree, both with honors, from Birla Institute of Technology in India.

For more information contact Dr. Baruch Ben Dor, President and CEO, InfraScan, Inc. at bbendor@earthlink.net.